Related Experiment Video
Updated: Jul 11, 2026

Multilevel Microdissection and Functional-Structural Profiling of Human Renal Arterial Branches
Published on: September 5, 2025
Frontiers in nephrology: early atherosclerosis--a view beyond the lumen
Mario Gossl1, Lilach O Lerman, Amir Lerman
1Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Insights
Microvascular endothelial dysfunction, involving the vasa vasorum and endothelial progenitor cells, may precede macrovascular issues in coronary artery disease. Therapies targeting these micro-aspects offer future cardiovascular disease prevention.
Area of Science:
- Cardiovascular Medicine
- Vascular Biology
- Atherosclerosis Research
Background:
- Endothelial dysfunction is a key marker for early coronary artery disease (CAD), linked to increased cardiovascular risk.
- Emerging concepts highlight microvascular and microcellular aspects of endothelial dysfunction preceding macrovascular changes.
- Proatherosclerotic changes in the vasa vasorum and endothelial progenitor cells (EPCs) may occur before evident CAD.
Purpose of the Study:
- To introduce and define microvascular endothelial dysfunction and microcellular endothelial dysfunction.
- To explore the role of vasa vasorum neovascularization and EPCs in early CAD.
- To propose future therapeutic strategies targeting microvascular and microcellular pathways.
Main Methods:
- Review of recent research on endothelial dysfunction in CAD.
- Conceptualization of microvascular and microcellular endothelial dysfunction.
- Discussion of vasa vasorum function and EPCs' role in atherogenesis.
Main Results:
- Microvascular endothelial dysfunction (vasa vasorum) and microcellular endothelial dysfunction (EPCs) may precede macrovascular endothelial dysfunction.
- Vasa vasorum neovascularization contributes to vessel wall inflammation and substance influx.
- Impaired EPC mobilization and function are implicated in CAD.
Conclusions:
- Microvascular and microcellular endothelial dysfunction represent early pathogenic mechanisms in CAD.
- Targeting vasa vasorum and EPCs offers novel therapeutic avenues for CAD prevention.
- Future interventions should focus on mitigating microvascular and microcellular endothelial dysfunction.
Abstract:
Endothelial dysfunction is an established clinical marker of early coronary artery disease and has been shown to be associated with increased cardiovascular morbidity and mortality. New concepts now extend the view of endothelial dysfunction beyond the traditional involvement of the coronary arterial endothelium alone. Recent research indicates that the coronary vessel wall, especially the vasa vasorum, as well as bone marrow-derived endothelial progenitor cells may be subject to proatherosclerotic changes, even before the development of angiographically evident endothelial dysfunction; therefore, "microvascular endothelial dysfunction," which is composed of dysfunction of the vasa vasorum's endothelium as well as "microcellular endothelial dysfunction," reflecting impaired mobilization and function of endothelial progenitor cells, may precede "macrovascular endothelial dysfunction." Vasa vasorum neovascularization, with endothelial leakage and dysfunction increasing influx of proinflammatory and proatherogenic cellular and noncellular substances into the vessel wall, is proposed as one feature of this new concept. In addition, the role of bone marrow-derived endothelial progenitor cells is discussed as are the potential impact of impaired progenitor cell mobilization, release from the marrow, and function in acute and stable coronary artery disease. Finally, potential future therapies are proposed, focusing on interventions that may prevent or diminish the development of the microvascular and microcellular endothelial dysfunction.
Related Concept Videos
Chronic Kidney Disease I: Introduction
Diabetic Nephropathy
Nephrons
Atherosclerosis I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury IV: Diagnostic Studies and Prevention